Trending

Kadcyla

Enhertu nabs speedy FDA review for earlier use in breast cancer

Enhertu nabs speedy FDA review for earlier use in breast cancer

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca

X

Enhertu nabs speedy FDA review for earlier use in breast cancer

https://pharmaphorum.com/news/enhertu-nabs-speedy-fda-review-for-earlier-use-in-breast-cancer/

ESMO21: Enhertu brings it’s A game to second-line breast cancer

ESMO21: Enhertu brings it’s A game to second-line breast cancer

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC)

X

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate

X

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

https://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/

Ambrx tries another IPO as it chases down HER2 rivals

Ambrx tries another IPO as it chases down HER2 rivals

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock

X

Ambrx tries another IPO as it chases down HER2 rivals

https://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

X

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

X

Exclusive Pfizer Speaker Interview Released

https://pharmaphorum.com/partner-content-oncology/exclusive-pfizer-speaker-interview-released/

What HCPs say about Roche’s breast cancer drug

What HCPs say about Roche’s breast cancer drug

The online conversations about breast cancer drug Kadcyla before it was approved by NICE.

X

What HCPs say about Roche’s breast cancer drug

https://pharmaphorum.com/views-and-analysis/roche-breast-cancer-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com